BioCentury
ARTICLE | Clinical News

Vapendavir: Phase IIb started

March 9, 2015 7:00 AM UTC

Biota began the double-blind, placebo-controlled, dose-ranging, international Phase IIb SPIRITUS trial to evaluate 264 and 528 mg oral vapendavir twice daily for 7 days in about 150 patients with mode...